Darren M. Kocs

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Hedy L. Kindler, Donald Richards, Lawrence Garbo et al. · Annals of Oncology · 2012 · 189 citations · Full text

Placebo-controlled Phase 2, Oncology, Pancreatic Cancer +10

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer

Matthew D. Galsky, Noah M. Hahn, Thomas Powles et al. · Clinical Genitourinary Cancer · 2012 · 85 citations

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +6

Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study

Donald Richards, Darren M. Kocs, Alexander I. Spira et al. · European Journal of Cancer · 2013 · 48 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +7

Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.

Darren M. Kocs, A. Mark Fendrick · PubMed · 2003 · 39 citations

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Mark A. Socinski, Robert N. Raju, Thomas E. Stinchcombe et al. · Journal of Thoracic Oncology · 2010 · 34 citations · Full text

Oncology, Phase Ii Trial, Medicine +8